Quantcast

Latest Boehringer Ingelheim Stories

2014-07-15 12:29:41

WASHINGTON and RIDGEFIELD, Conn., July 15, 2014 /PRNewswire-USNewswire/ -- NCLR (National Council of La Raza) today released a report

2014-07-08 08:30:12

- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ --

2014-06-27 08:25:26

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human

2014-06-27 08:25:19

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human

2014-06-26 08:28:27

Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.

2014-06-23 23:03:39

Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration – Boehringer Ingelheim Pharmaceuticals, Inc.

2014-06-19 23:17:50

Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa.

2014-06-19 23:17:47

German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related